Media coverage about Sorrento Therapeutics (NASDAQ:SRNE) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sorrento Therapeutics earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 48.1252526348306 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have impacted Accern’s scoring:

NASDAQ SRNE opened at $4.95 on Monday. Sorrento Therapeutics has a 1-year low of $1.67 and a 1-year high of $10.65. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.39 and a current ratio of 1.39.

Several research firms have recently weighed in on SRNE. ValuEngine downgraded Sorrento Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright set a $40.00 target price on Sorrento Therapeutics and gave the company a “buy” rating in a research report on Monday, May 14th. BidaskClub upgraded Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 25th. TheStreet downgraded Sorrento Therapeutics from a “c-” rating to a “d+” rating in a research report on Tuesday, July 24th. Finally, B. Riley began coverage on Sorrento Therapeutics in a research report on Thursday, June 28th. They issued a “buy” rating and a $14.25 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.08.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells.

Featured Story: Risk Tolerance and Your Investment Decisions

Insider Buying and Selling by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with's FREE daily email newsletter.